A Phase 1b Multicenter, Open-label Study To Evaluate The Safety And Tolerability And Determine The Maximum Tolerated Dose Of Pf-05230907 In Subjects With Intracerebral Hemorrhage (Ich)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs PF 5230907 (Primary)
- Indications Cerebral haemorrhage
- Focus Adverse reactions
- Sponsors Pfizer
- 15 Dec 2017 Planned End Date changed from 18 Jun 2018 to 22 Jan 2018.
- 15 Dec 2017 Planned primary completion date changed from 18 Jun 2018 to 22 Jan 2018.
- 15 Dec 2017 Status changed from recruiting to active, no longer recruiting.